Abbott: FDA Approves Amplatzer Piccolo Occluder Medical Device - Quick Facts


(RTTNews.com) - Abbott Laboratories ( ABT ) said Monday that the U.S. Food and Drug Administration or FDA approved the Amplatzer Piccolo Occluder, the world's first medical device that can be implanted in the tiniest babies - weighing as little as two pounds - using a minimally invasive procedure to treat patent ductus arteriosus, or PDA.

Abbott noted that the Amplatzer Piccolo, a device even smaller than a small pea, now offers hope to premature infants and newborns who need corrective treatment, and who may be non-responsive to medical management and high risk to undergo corrective surgery.

One of the most common congenital heart defects occurring in premature babies, PDA is a potentially life-threatening opening between two blood vessels leading from the heart. This channel, which is present in normally developing fetuses, is important prior to birth to allow oxygen-rich blood from the mother to circulate throughout the fetus' body.

For most infants, the pathway, or duct, seals itself shortly after birth. In some cases, primarily in babies born prematurely, the PDA fails to spontaneously close, which can make it difficult for babies to breathe normally due to increased blood flow to the lungs. PDA accounts for up to 10 percent of all congenital heart disease.

About 60,000 premature babies in the U.S. are born each year with a very low birth weight, and nearly 12,000, or one out of five, of these have a hemodynamically significant PDA - a PDA that is large and causes symptoms - which will require urgent treatment for the baby to survive.

According to Abbott, the Amplatzer Piccolo Occluder is a self-expanding, wire mesh device that is inserted through a small incision in the leg and guided through vessels to the heart, where it is placed to seal the opening in the heart.

It is designed to allow the physician to insert it through the aortic or pulmonary artery, as well as to retrieve and redeploy the device for optimal placement. Because the device is deployed in a minimally invasive procedure, many of the premature babies who are critically ill in the neonatal intensive care unit are able to be weaned from artificial respirator support soon after the procedure.


Read the original article on RTTNews (http://www.rttnews.com/2969295/abbott-fda-approves-amplatzer-piccolo-occluder-medical-device-quick-facts.aspx)


For comments and feedback: contact editorial@rttnews.com




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of NASDAQ, Inc.